Optimization for a novel therapy targeting bacterial toxins in severe infections

• Unité de recherche: INNOSUISSE
• Numéro de projet: 16001.1;9 PFLS-LS
• Titre du projet anglais: Optimization for a novel therapy targeting bacterial toxins in severe infections

Description succincte (Allemand)

Optimization for a novel therapy targeting bacterial toxins in severe infections

Description succincte (Anglais)

Optimization for a novel therapy targeting bacterial toxins in severe infections

Résumé des résultats (Abstract) (Allemand)

CAL02 is a non-antibiotic drug for severe bacterial infections that targets toxins and whose potency has been demonstrated in vitro and in vivo against various toxins and relevant bacterial strains. CAL02 has now been manufactured according to a new process optimized for GMP production and up-scaling. The proposed project?s objective is to optimize in vitro experiments for the validation of the GMP-enabled batch and provide key answers in order to get regulatory Scientific Advice with a view to launching a first clinical trial.

Résumé des résultats (Abstract) (Anglais)

CAL02 is a non-antibiotic drug for severe bacterial infections that targets toxins and whose potency has been demonstrated in vitro and in vivo against various toxins and relevant bacterial strains. CAL02 has now been manufactured according to a new process optimized for GMP production and up-scaling. The proposed project?s objective is to optimize in vitro experiments for the validation of the GMP-enabled batch and provide key answers in order to get regulatory Scientific Advice with a view to launching a first clinical trial.